JP2017504649A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017504649A5 JP2017504649A5 JP2016549388A JP2016549388A JP2017504649A5 JP 2017504649 A5 JP2017504649 A5 JP 2017504649A5 JP 2016549388 A JP2016549388 A JP 2016549388A JP 2016549388 A JP2016549388 A JP 2016549388A JP 2017504649 A5 JP2017504649 A5 JP 2017504649A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- nonalcoholic
- composition according
- group
- fatty liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 50
- 239000008194 pharmaceutical composition Substances 0.000 claims description 39
- 229960001713 canagliflozin Drugs 0.000 claims description 34
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 claims description 34
- 208000004930 Fatty Liver Diseases 0.000 claims description 29
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 29
- 208000010706 fatty liver disease Diseases 0.000 claims description 29
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 29
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 25
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 208000035475 disorder Diseases 0.000 claims description 19
- 239000005541 ACE inhibitor Substances 0.000 claims description 17
- 229940125364 angiotensin receptor blocker Drugs 0.000 claims description 17
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 17
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 12
- 230000001476 alcoholic effect Effects 0.000 claims description 12
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 12
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims description 10
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims description 10
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 9
- 239000002083 C09CA01 - Losartan Substances 0.000 claims description 8
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 8
- 108010061435 Enalapril Proteins 0.000 claims description 8
- 206010016654 Fibrosis Diseases 0.000 claims description 8
- 108010007859 Lisinopril Proteins 0.000 claims description 8
- 230000007882 cirrhosis Effects 0.000 claims description 8
- 229960000873 enalapril Drugs 0.000 claims description 8
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 8
- 229960001195 imidapril Drugs 0.000 claims description 8
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 claims description 8
- 229960002198 irbesartan Drugs 0.000 claims description 8
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims description 8
- 229960002394 lisinopril Drugs 0.000 claims description 8
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims description 8
- 229960004773 losartan Drugs 0.000 claims description 8
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 8
- 229960003401 ramipril Drugs 0.000 claims description 8
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims description 8
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims description 7
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 208000008589 Obesity Diseases 0.000 claims description 6
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 229960005095 pioglitazone Drugs 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 229960004586 rosiglitazone Drugs 0.000 claims description 6
- 229960001641 troglitazone Drugs 0.000 claims description 6
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims description 6
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims description 6
- 102000009027 Albumins Human genes 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 4
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical group C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims description 4
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 4
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims description 4
- 208000033626 Renal failure acute Diseases 0.000 claims description 4
- 201000011040 acute kidney failure Diseases 0.000 claims description 4
- 208000012998 acute renal failure Diseases 0.000 claims description 4
- 229960004530 benazepril Drugs 0.000 claims description 4
- 229960000932 candesartan Drugs 0.000 claims description 4
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims description 4
- 229960000830 captopril Drugs 0.000 claims description 4
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 4
- 208000020832 chronic kidney disease Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000002485 urinary effect Effects 0.000 claims description 4
- 229960004699 valsartan Drugs 0.000 claims description 4
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 3
- 102000000536 PPAR gamma Human genes 0.000 claims description 3
- 108010016731 PPAR gamma Proteins 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 3
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 claims description 3
- 229950001628 netoglitazone Drugs 0.000 claims description 3
- -1 riboglitazone Chemical compound 0.000 claims description 3
- 206010027525 Microalbuminuria Diseases 0.000 claims description 2
- 230000001447 compensatory effect Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 230000001434 glomerular Effects 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 description 57
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 18
- 208000024891 symptom Diseases 0.000 description 15
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 4
- 208000001280 Prediabetic State Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 201000009104 prediabetes syndrome Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 2
- 229950009226 ciglitazone Drugs 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 210000001596 intra-abdominal fat Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003312 cholesterol blood level Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461934003P | 2014-01-31 | 2014-01-31 | |
| US61/934,003 | 2014-01-31 | ||
| US201461948882P | 2014-03-06 | 2014-03-06 | |
| US61/948,882 | 2014-03-06 | ||
| PCT/US2015/013644 WO2015116880A1 (en) | 2014-01-31 | 2015-01-30 | Methods for the treatment and prevention of renal disorders and fatty liver disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020005106A Division JP2020090511A (ja) | 2014-01-31 | 2020-01-16 | 腎障害及び脂肪性肝障害の治療並びに予防のための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017504649A JP2017504649A (ja) | 2017-02-09 |
| JP2017504649A5 true JP2017504649A5 (enExample) | 2018-03-08 |
Family
ID=52544570
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549388A Withdrawn JP2017504649A (ja) | 2014-01-31 | 2015-01-30 | 腎障害及び脂肪性肝障害の治療並びに予防のための方法 |
| JP2020005106A Pending JP2020090511A (ja) | 2014-01-31 | 2020-01-16 | 腎障害及び脂肪性肝障害の治療並びに予防のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020005106A Pending JP2020090511A (ja) | 2014-01-31 | 2020-01-16 | 腎障害及び脂肪性肝障害の治療並びに予防のための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20160339047A1 (enExample) |
| EP (1) | EP3099328A1 (enExample) |
| JP (2) | JP2017504649A (enExample) |
| KR (1) | KR20160107344A (enExample) |
| CN (3) | CN105939728A (enExample) |
| AU (2) | AU2015210898A1 (enExample) |
| CA (1) | CA2938406A1 (enExample) |
| EA (1) | EA201691555A1 (enExample) |
| IL (1) | IL246779A0 (enExample) |
| MX (1) | MX2016010011A (enExample) |
| WO (1) | WO2015116880A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018532720A (ja) * | 2015-09-16 | 2018-11-08 | トビラ セラピューティクス， インコーポレイテッド | 線維症の治療のためのセニクリビロック併用療法 |
| ES2979120T3 (es) * | 2015-11-06 | 2024-09-24 | Gelteq Ltd | Método y producto para evaluar la respuesta a una carga oral de glucosa |
| GB201614455D0 (en) | 2016-08-24 | 2016-10-05 | Univ Oxford Innovation Ltd | Biomarkers |
| TWI835735B (zh) * | 2017-06-12 | 2024-03-21 | 比利時商健生藥品公司 | 減少或預防第ii型糖尿病患者中心血管事件之方法 |
| CN109806397A (zh) * | 2017-11-20 | 2019-05-28 | 江苏恒瑞医药股份有限公司 | Sglt2抑制剂与arb联合在制备治疗高血压等疾病的药物中的用途 |
| CN111405899B (zh) | 2017-11-30 | 2025-05-16 | 爱杜西亚药品有限公司 | 用于治疗内皮素相关疾病的4-嘧啶磺酰胺衍生物与sglt-2抑制剂的组合 |
| TW202103709A (zh) * | 2019-03-26 | 2021-02-01 | 比利時商健生藥品公司 | 用於治療患有慢性腎臟病之對象的方法 |
| CN110051851A (zh) * | 2019-05-31 | 2019-07-26 | 江苏苏中药业集团股份有限公司 | 一种钠-葡萄糖共转运蛋白-2抑制剂与黄蜀葵花提取物的组合 |
| EP4197543A4 (en) * | 2020-08-17 | 2024-05-15 | Beijing Creatron Institute of Pharmaceutical Research Co., Ltd. | COMPOSITION AND USE OF SGLT-2 INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS |
| CA3197706A1 (en) * | 2020-10-30 | 2022-05-05 | Resverlogix Corp. | Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| CN116234545A (zh) * | 2020-11-19 | 2023-06-06 | 北京睿创康泰医药研究院有限公司 | 固定剂量的sglt-2抑制剂与血管紧张素转化酶抑制剂的组合物及用途 |
| JP2024094532A (ja) | 2022-12-28 | 2024-07-10 | キヤノン株式会社 | 撮像設定装置および撮像装置 |
| KR20240126452A (ko) * | 2023-02-10 | 2024-08-21 | 가천대학교 산학협력단 | 칸데사르탄 또는 아질사르탄을 포함하는 조성물의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ313897A3 (cs) * | 1995-04-07 | 1998-01-14 | Novartis Ag | Farmaceutické kompozice obsahující benazepril nebo benazeprilát a valsartan |
| ES2531660T3 (es) | 2003-08-01 | 2015-03-18 | Mitsubishi Tanabe Pharma Corporation | Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio |
| UY30730A1 (es) * | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| WO2008113095A1 (en) * | 2007-03-20 | 2008-09-25 | Fibrotech Therapeutics Pty Ltd | Compositions and therapies comprising tranilast compounds and angiotensin-converting enzyme (ace) inhibitors and/or angiotensin receptor blockers (arb) |
| UY32030A (es) * | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| JP2012510511A (ja) * | 2008-12-01 | 2012-05-10 | インヴアスク セラピューテイックス インコーポレイテッド | レニン−アンジオテンシン−アルドステロン系阻害剤及びリポ酸化合物を含有する組成物、並びに、レニン−アンジオテンシン−アルドステロン系に関連した疾患の治療のためのそれらの使用 |
| CA2756779C (en) * | 2009-03-26 | 2019-10-29 | Ajay Gupta | Compositions and methods for treatment of renal disease |
| EP2552442A1 (en) * | 2010-03-30 | 2013-02-06 | Boehringer Ingelheim International GmbH | Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof |
| ES2687027T3 (es) * | 2010-11-04 | 2018-10-23 | Albireo Ab | Inhibidores de ibat para el tratamiento de enfermedades hepáticas |
| SG190204A1 (en) * | 2010-11-11 | 2013-06-28 | Redx Pharma Ltd | Drug derivatives |
| AR083878A1 (es) * | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
-
2015
- 2015-01-30 AU AU2015210898A patent/AU2015210898A1/en not_active Abandoned
- 2015-01-30 CN CN201580006608.8A patent/CN105939728A/zh active Pending
- 2015-01-30 EP EP15705743.1A patent/EP3099328A1/en not_active Withdrawn
- 2015-01-30 MX MX2016010011A patent/MX2016010011A/es unknown
- 2015-01-30 KR KR1020167023439A patent/KR20160107344A/ko not_active Ceased
- 2015-01-30 WO PCT/US2015/013644 patent/WO2015116880A1/en not_active Ceased
- 2015-01-30 CN CN202110463410.XA patent/CN113082021A/zh active Pending
- 2015-01-30 CA CA2938406A patent/CA2938406A1/en not_active Abandoned
- 2015-01-30 EA EA201691555A patent/EA201691555A1/ru unknown
- 2015-01-30 JP JP2016549388A patent/JP2017504649A/ja not_active Withdrawn
- 2015-01-30 US US15/112,786 patent/US20160339047A1/en not_active Abandoned
- 2015-01-30 CN CN202110463431.1A patent/CN113144204A/zh active Pending
-
2016
- 2016-07-14 IL IL246779A patent/IL246779A0/en unknown
-
2018
- 2018-07-20 US US16/040,580 patent/US20180344756A1/en not_active Abandoned
-
2020
- 2020-01-16 JP JP2020005106A patent/JP2020090511A/ja active Pending
- 2020-12-02 AU AU2020281039A patent/AU2020281039A1/en not_active Abandoned
-
2021
- 2021-01-05 US US17/141,248 patent/US20210121492A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017504649A5 (enExample) | ||
| TWI735546B (zh) | 使用fxr促效劑之方法 | |
| Anabtawi et al. | Metformin: nonglycemic effects and potential novel indications | |
| US20120071451A1 (en) | Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid | |
| EP3411026B1 (en) | Use of stimulators of soluble guanylate cyclase for the treatment of nonalcoholic steatohepatitis (nash) | |
| WO2015005365A1 (ja) | 非アルコール性脂肪性肝疾患治療剤 | |
| JP7763436B2 (ja) | アルカリ性化剤による血液浄化 | |
| JP2010516691A (ja) | 抗炎症剤及びキサンチン酸化還元酵素阻害剤を用いて痛風の突発を抑え、又はその数を減少させる方法 | |
| CN108882744B (zh) | 含有益智提取物的组合物以及益智提取物的用途 | |
| CN113301889A (zh) | Nafld和nash的联合治疗 | |
| CN105939728A (zh) | 用于治疗和预防肾病和脂肪肝病的方法 | |
| CN113908158A (zh) | 使用fxr激动剂的方法 | |
| US20180008665A1 (en) | Methods of treating and preventing gout and lead nephropathy | |
| JP6915050B2 (ja) | Ｆｘｒアゴニストの新規のレジーム | |
| CN111093705A (zh) | 包含fxr激动剂的组合 | |
| Katavetin et al. | Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy | |
| CN103648498A (zh) | 药物组合物 | |
| WO2018051230A1 (en) | Combination of fxr agonists | |
| JP6509729B2 (ja) | 慢性腎臓病の進行抑制又は改善剤 | |
| Dutta et al. | The Link Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Gastroesophageal Reflux Disease | |
| CN102892760B (zh) | 非醇性脂肪性肝炎的预防和/或治疗剂 | |
| EP3302460A1 (en) | Sacubitril and valsartan for treating metabolic disease | |
| US20160030415A1 (en) | Treatment and prophylaxis of kidney diseases | |
| CN115335055A (zh) | 用于预防或治疗非酒精性脂肪性肝炎的药物组合物 | |
| JP2012197274A (ja) | Ｐｄｅ５阻害剤含有医薬組成物 |